Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile

Cell Cycle

Volumn 13, Issue 7, 2014, Pages 1132-1144

  Oliveras Ferraros, Cristina ^a,b   Vazquez Martin, Alejandro ^a,b   Cuyas̀, Elisabet ^a,b   Corominas Faja, Bruna ^a,b   Rodriǵuez Gallego, Esther ^c   Fernańdez Arroyo, Salvador ^c   Martin Castillo, Begoña ^a,b   Joven, Jorge ^c   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

AMPK; Breast cancer; Degradome; Metabolism; Metastasis; Metformin

Indexed keywords

BETA SECRETASE 2; CELL CYCLE PROTEIN 20; CENTROMERE PROTEIN A; CYTOSOLIC PHOSPHOLIPASE A2; KALLIKREIN; KALLIKREIN 11; MATRIX METALLOPROTEINASE 16; METFORMIN; MUCIN 1; PROTEIN BCL 2; TRANSCRIPTOME; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CELL GROWTH; CELL INTERACTION; CELL INVASION; CELL MIGRATION; DNA DAMAGE CHECKPOINT; DOWN REGULATION; DRUG MECHANISM; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETIC CODE; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; METASTASIS; NUCLEAR REPROGRAMMING; TUMOR MICROENVIRONMENT; UPREGULATION; BREAST TUMOR; DRUG RESISTANCE; GENE EXPRESSION PROFILING; MCF-7 CELL LINE; METABOLISM; PATHOLOGY;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; MCF-7 CELLS; METFORMIN; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; TRANSCRIPTOME;

EID: 84897987462     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27982     Document Type: Article

References (105)

1. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13:714-26; PMID:24060863; http://dx.doi.org/10.1038/nrc3599
2. Muñoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012; 3:e248; PMID:22237205; http://dx.doi.org/10.1038/cddis.2011.123
3. Butler EB, Zhao Y, Muñoz-Pinedo C, Lu J, Tan M. Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res 2013; 73:2709-17; PMID:23610447; http://dx.doi.org/10.1158/0008-5472. CAN-12-3009
4. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013; 12:829-46; PMID:24113830; http://dx.doi.org/10.1038/nrd4145
5. Sotgia F, Martinez-Outschoorn UE, Lisanti MP. Cancer metabolism: new validated targets for drug discovery. Oncotarget 2013; 4:1309-16; PMID:23896568
6. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4:e532; PMID:23470539; http://dx.doi.org/10. 1038/cddis.2013.60
7. Menendez JA, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, López-Bonet E, Alarcón T, Vazquez-Martin A. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle 2013; 12:1166-79; PMID:23549172; http://dx.doi.org/10.4161/cc.24479
8. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, López-Bonet E, Martin-Castillo B, Joven J, Menendez JA. The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. Sci Rep 2013; 3:2469; PMID:23965851; http://dx.doi.org/10.1038/srep02469
9. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget 2012; 3:1600-14; PMID:23307622
10. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B, Menendez JA. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 2012; 3:395-8; PMID:22565037
11. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69:7507-11; PMID:19752085; http://dx.doi.org/10.1158/0008-5472.CAN-09-2994
12. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011; 71:3196-201; PMID:21415163; http://dx.doi.org/10.1158/0008-5472.CAN-10-3471
13. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012; 18:290-300; PMID:22090360; http://dx.doi.org/10.1158/1078-0432.CCR-11-2260
14. Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G, Tsakiridis T. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 2013; 108:2021-32; PMID:23632475; http://dx.doi.org/10.1038/bjc. 2013.187
15. Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, Glicksman R, Chaib S, Zamiara P, Milosevic M, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 2013; 19:6741-50; PMID:24141625; http://dx.doi.org/10.1158/1078-0432.CCR- 13-1787
16. Lonardo E, Cioffi M, Sancho P, Sanchez-Ripoll Y, Trabulo SM, Dorado J, Balic A, Hidalgo M, Heeschen C. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One 2013; 8:e76518; PMID:24204632; http://dx.doi.org/10.1371/journal.pone.0076518
17. Pollak M. Potential applications for biguanides in oncology. J Clin Invest 2013; 123:3693-700; PMID:23999444; http://dx.doi.org/10.1172/JCI67232
18. Morgillo F, Sasso FC, Della Corte CM, Festino L, Manzo A, Martinelli E, Troiani T, Capuano A, Ciardiello F. Metformin in lung cancer: rationale for a combination therapy. Expert Opin Investig Drugs 2013; 22:1401-9; PMID:23937224; http://dx.doi.org/10.1517/13543784.2013.828691
19. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A 2013; 110:972-7; PMID:23277563; http://dx.doi.org/10. 1073/pnas.1221055110
20. Komurov K, Tseng JT, Muller M, Seviour EG, Moss TJ, Yang L, Nagrath D, Ram PT. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 2012; 8:596; PMID:22864381; http://dx.doi.org/10.1038/msb.2012.25
21. Locasale JW. Metabolic rewiring drives resistance to targeted cancer therapy. Mol Syst Biol 2012; 8:597; PMID:22806144; http://dx.doi.org/10.1038/ msb.2012.30
22. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7:11-20; PMID:18177721; http://dx.doi.org/10.1016/j.cmet.2007.10.002
23. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23:537-48; PMID:19270154; http://dx.doi.org/10.1101/gad.1756509
24. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33; PMID:19460998; http://dx.doi.org/10.1126/science.1160809
25. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297-308; PMID:22439925; http://dx.doi.org/10.1016/j.ccr.2012.02.014
26. Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, Del Barco S, Menendez JA. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinicaltranslational research experience at the Catalan Institute of Oncology. Ann Oncol 2010; 21:187-9; PMID:19884247; http://dx.doi.org/10.1093/annonc/mdp494
27. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9:1057-64; PMID:20305377; http://dx.doi.org/10.4161/ cc.9.6.10994
28. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. The antidiabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011; 126:355-64; PMID:20458531; http://dx.doi.org/10.1007/s10549-010-0924-x
29. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Curr Mol Med 2010; 10:674-91; PMID:20712585; http://dx.doi.org/10.2174/156652410792630625
30. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896-917; PMID:22203527
31. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Menendez OJ, Bosch-Barrera J, Martin-Castillo B, Joven J, Menendez JA. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle 2012; 11:865-70; PMID:22333588; http://dx.doi.org/10.4161/cc.11.5.19252
32. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Quirantes R, Segura-Carretero A, Micol V, Joven J, Bosch-Barrera J, Del Barco S, Martin-Castillo B, et al. Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle 2012; 11:1235-46; PMID:22356767; http://dx.doi.org/10.4161/cc.11.6.19665
33. Menendez JA, Oliveras-Ferraros C, Cufí S, Corominas-Faja B, Joven J, Martin-Castillo B, Vazquez-Martin A. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 2012; 11:2782-92; PMID:22809961; http://dx.doi.org/10.4161/cc.20948
34. Corominas-Faja B, Quirantes-Piné R, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Martin-Castillo B, Micol V, Joven J, Segura-Carretero A, Menendez JA. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) 2012; 4:480-98; PMID:22837425
35. Vazquez-Martin A, Cufi S, Lopez-Bonet E, Corominas-Faja B, Oliveras-Ferraros C, Martin-Castillo B, Menendez JA. Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep 2012; 2:964; PMID:23236586; http://dx.doi.org/10.1038/srep00964
36. Menendez JA, Joven J. One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin. Aging (Albany NY) 2012; 4:894-8; PMID:23525940
37. Cufí S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, López IÁ, Dorca J, Martínez S, López NB, Fernández SD, et al. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget 2013; 4:1484-95; PMID:23986086
38. Yamaguchi R, Perkins G. Finding a Panacea among combination cancer therapies. Cancer Res 2012; 72:18-23; PMID:22052464; http://dx.doi.org/10.1158/ 0008-5472.CAN-11-3091
39. Yamaguchi R, Perkins G. Challenges in targeting cancer metabolism for cancer therapy. EMBO Rep 2012; 13:1034-5; PMID:23146898; http://dx.doi.org/10. 1038/embor.2012.176
40. Robinson GL, Dinsdale D, Macfarlane M, Cain K. Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene 2012; 31:4996-5006; PMID:22310286; http://dx.doi.org/10.1038/onc.2012.13
41. Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, Zamboni N, Schulze A. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov 2012; 2:328-43; PMID:22576210; http://dx.doi.org/10.1158/2159- 8290.CD-11-0234
42. Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002; 62:295-300; PMID:11782391
43. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 2003; 63:6543-6; PMID:14559849
44. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007; 249:61-79; PMID:17275179; http://dx.doi.org/10.1016/j.canlet.2006.12.018
45. Kontos CK, Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med 2012; 50:1877-91; PMID:23093268; http://dx.doi.org/10.1515/cclm-2012-0247
46. Borgoño CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004; 2:257-80; PMID:15192120
47. Puente XS, Sánchez LM, Overall CM, López-Otín C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003; 4:544-58; PMID:12838346; http://dx.doi.org/10.1038/nrg1111
48. Quesada V, Ordóñez GR, Sánchez LM, Puente XS, López-Otín C. The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res 2009; 37:D239-43; PMID:18776217; http://dx.doi.org/10.1093/nar/gkn570
49. Ordóñez GR, Puente XS, Quesada V, López-Otín C. Proteolytic systems: constructing degradomes. Methods Mol Biol 2009; 539:33-47; PMID:19377972; http://dx.doi.org/10.1007/978-1-60327-003-8-2
50. Fraile JM, Ordóñez GR, Quirós PM, Astudillo A, Galván JA, Colomer D, López-Otín C, Freije JM, Puente XS. Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. Oncotarget 2013; 4:1931-2; PMID:24243807
51. Shahinian H, Loessner D, Biniossek ML, Kizhakkedathu JN, Clements JA, Magdolen V, Schilling O. Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells. Mol Oncol 2014; 8:68-82; PMID:24120346
52. Sano A, Sangai T, Maeda H, Nakamura M, Hasebe T, Ochiai A. Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int J Oncol 2007; 30:1493-8; PMID:17487371
53. Santamaría I, Velasco G, Pendás AM, Paz A, López-Otín C. Molecular cloning and structural and functional characterization of human cathepsin F, a new cysteine proteinase of the papain family with a long propeptide domain. J Biol Chem 1999; 274:13800-9; PMID:10318784; http://dx.doi.org/10.1074/jbc.274.20.13800
54. Krueger S, Kellner U, Buehling F, Roessner A. Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype. Cancer Gene Ther 2001; 8:522-8; PMID:11498774; http://dx.doi.org/10. 1038/sj.cgt.7700341
55. Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza P, Garcia JA, Salcedo M. Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer 2005; 5:68; PMID:15989693; http://dx.doi.org/10.1186/1471-2407-5-68
56. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6:764-75; PMID:16990854; http://dx.doi.org/10.1038/ nrc1949
57. López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7:800-8; PMID:17851543; http://dx.doi.org/10.1038/nrc2228
58. Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 2008; 29:22-8; PMID:18037508; http://dx.doi.org/10.1016/j.tips.2007.10.011
59. Obermajer N, Jevnikar Z, Doljak B, Kos J. Role of cysteine cathepsins in matrix degradation and cell signalling. Connect Tissue Res 2008; 49:193-6; PMID:18661341; http://dx.doi.org/10.1080/03008200802143158
60. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010; 14:1091-108; PMID:20819019; http://dx.doi.org/10. 1517/14728222.2010.519701
61. Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biol Ther 2012; 13:1143-51; PMID:22892844; http://dx.doi.org/10.4161/cbt.21354
62. Walczak H. Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol 2013; 5:a008698; PMID:23637280; http://dx.doi.org/10.1101/cshperspect.a008698
63. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013; 32:1341-50; PMID:22580613; http://dx.doi.org/10.1038/onc.2012.164
64. Crowder RN, El-Deiry WS. Caspase-8 regulation of TRAIL-mediated cell death. Exp Oncol 2012; 34:160-4; PMID:23070000
65. Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM, Rabinowich H. Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 2008; 283:19665-77; PMID:18375389; http://dx.doi.org/ 10.1074/jbc.M710169200
66. Hou W, Han J, Lu C, Goldstein LA, Rabinowich H. Enhancement of tumor-TRAIL susceptibility by modulation of autophagy. Autophagy 2008; 4:940-3; PMID:18769107
67. Herrero-Martín G, Høyer-Hansen M, García- García C, Fumarola C, Farkas T, López-Rivas A, JäätteläM. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J 2009; 28:677-85; PMID:19197243; http://dx.doi.org/10.1038/emboj.2009.8
68. Hou W, Han J, Lu C, Goldstein LA, Rabinowich H. Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis. Autophagy 2010; 6:891-900; PMID:20724831; http://dx.doi.org/10.4161/auto.6.7. 13038
69. Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 2008; 4:600-6; PMID:18497563
70. Germain M, Slack RS. Dining in with BCL-2: new guests at the autophagy table. Clin Sci (Lond) 2010; 118:173-81; PMID:19845510; http://dx.doi.org/10. 1042/CS20090310
71. Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 2011; 278:403-13; PMID:21182587; http://dx.doi.org/10.1111/j.1742-4658.2010.07965.x
72. He W, Wang Q, Xu J, Xu X, Padilla MT, Ren G, Gou X, Lin Y. Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy 2012; 8:1811-21; PMID:23051914; http://dx.doi.org/10.4161/auto.22145
73. Chen LC, Chen CC, Liang Y, Tsang NM, Chang YS, Hsueh C. A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma. Mod Pathol 2011; 24:175-84; PMID:21057457; http://dx.doi.org/10.1038/ modpathol.2010.193
74. Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet 2013; 45:98-103; PMID:23202126; http://dx.doi.org/10.1038/ng.2481
75. Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG, et al. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS One 2013; 8:e73940; PMID:24040120; http://dx.doi.org/10.1371/journal.pone. 0073940
76. Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 2014; 146:245-56; PMID:24096005
77. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5:744-9; PMID:16148886; http://dx.doi.org/10.1038/nrc1694
78. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11:1487-95; PMID:19935649; http://dx.doi.org/10.1038/ncb1998
79. Brabletz T. To differentiate or not - routes towards metastasis. Nat Rev Cancer 2012; 12:425-36; PMID:22576165; http://dx.doi.org/10.1038/nrc3265
80. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell 2012; 22:699-701; PMID:23238008; http://dx.doi.org/10.1016/j.ccr. 2012.11.009
81. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010; 140:49-61; PMID:20079333; http://dx.doi.org/10.1016/j. cell.2009.11.027
82. Ye L, Zhang B, Seviour EG, Tao KX, Liu XH, Ling Y, Chen JY, Wang GB. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett 2011; 307:6-17; PMID:21543155; http://dx.doi.org/10.1016/j.canlet.2011.03.007
83. Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, Hoover HH, Cravatt BF. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 2011; 18:846-56; PMID:21802006; http://dx.doi.org/10.1016/j.chembiol.2011.05.009
84. Fowler CJ. Monoacylglycerol lipase - a target for drug development? Br J Pharmacol 2012; 166:1568-85; PMID:22428756; http://dx.doi.org/10.1111/j.1476- 5381.2012.01950.x
85. Mulvihill MM, Nomura DK. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci 2013; 92:492-7; PMID:23142242; http://dx.doi.org/10.1016/ j.lfs.2012.10.025
86. Louie SM, Roberts LS, Mulvihill MM, Luo K, Nomura DK. Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids. Biochim Biophys Acta 2013; 1831:1566-72; PMID:23872477; http://dx.doi.org/10.1016/j.bbalip.2013.07.008
87. Smyth I, Du X, Taylor MS, Justice MJ, Beutler B, Jackson IJ. The extracellular matrix gene Frem1 is essential for the normal adhesion of the embryonic epidermis. Proc Natl Acad Sci U S A 2004; 101:13560-5; PMID:15345741; http://dx.doi.org/10.1073/pnas.0402760101
88. Pavlakis E, Chiotaki R, Chalepakis G. The role of Fras1/Frem proteins in the structure and function of basement membrane. Int J Biochem Cell Biol 2011; 43:487-95; PMID:21182980; http://dx.doi.org/10.1016/j.biocel.2010.12.016
89. Ji J, Jia S, Ji K, Jiang WG. Wnt1 inducible signalling pathway protein-2 (WISP-2/CCN5): Roles and regulation in human cancers Oncol Rep 2013; http://dx.doi.org/10.3892/or.2013.2909
90. Russo JW, Castellot JJ. CCN5: biology and pathophysiology. J Cell Commun Signal 2010; 4:119-30; PMID:21063502; http://dx.doi.org/10.1007/s12079-010-0098- 7
91. Fabbretti E, Edomi P, Brancolini C, Schneider C. Apoptotic phenotype induced by overexpression of wild-type gas3/PMP22: its relation to the demyelinating peripheral neuropathy CMT1A. Genes Dev 1995; 9:1846-56; PMID:7649472; http://dx.doi.org/10.1101/gad.9.15.1846
92. Li YJ, Liu G, Li Y, Vecchiarelli-Federico LM, Liu JC, Zacksenhaus E, Shan SW, Yang BB, Li Q, Dash R, et al. mda-7/IL-24 Expression inhibits breast cancer through upregulation of growth arrest-specific gene 3 (gas3) and disruption of β1 integrin function. Mol Cancer Res 2013; 11:593-603; PMID:23468528; http://dx.doi.org/10.1158/1541-7786.MCR-12-0496
93. Kim G, Chung JY, Jun SY, Eom DW, Bae YK, Jang KT, Kim J, Yu E, Hong SM. Loss of S100A14 expression is associated with the progression of adenocarcinomas of the small intestine. Pathobiology 2013; 80:95-101; PMID:23038644; http://dx.doi.org/10.1159/000342394
94. Sapkota D, Costea DE, Blø M, Bruland O, Lorens JB, Vasstrand EN, Ibrahim SO. S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest. Oral Oncol 2012; 48:219-25; PMID:22032898; http://dx.doi.org/10.1016/j.oraloncology.2011.10.001
95. Roll JD, Rivenbark AG, Sandhu R, Parker JS, Jones WD, Carey LA, Livasy CA, Coleman WB. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Exp Mol Pathol 2013; 95:276-87; PMID:24045095; http://dx.doi.org/10.1016/j.yexmp.2013.09.001
96. Menezes ME, Devine DJ, Shevde LA, Samant RS. Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer 2012; 130:1477-83; PMID:21953410; http://dx.doi.org/10.1002/ijc.26449
97. Qi L, Sun B, Liu Z, Li H, Gao J, Leng X. Dickkopf-1 inhibits epithelial-mesenchymal transition of colon cancer cells and contributes to colon cancer suppression. Cancer Sci 2012; 103:828-35; PMID:22321022; http://dx.doi.org/10.1111/j.1349-7006.2012.02222.x
98. Barbolina MV, Liu Y, Gurler H, Kim M, Kajdacsy-Balla AA, Rooper L, Shepard J, Weiss M, Shea LD, Penzes P, et al. Matrix rigidity activates Wnt signaling through down-regulation of Dickkopf-1 protein. J Biol Chem 2013; 288:141-51; PMID:23152495; http://dx.doi.org/10.1074/jbc.M112.431411
99. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009; 69:5364-73; PMID:19549913; http://dx.doi.org/10.1158/0008-5472. CAN-08-4135
100. Mitra A, Menezes ME, Shevde LA, Samant RS. DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype. J Biol Chem 2010; 285:24686-94; PMID:20522561; http://dx.doi.org/10.1074/jbc.M109.094847
101. Marignac VM, Smith S, Toban N, Bazile M, Aloyz R. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget 2013
102. Erenpreisa J, Cragg MS. Cancer: a matter of life cycle? Cell Biol Int 2007; 31:1507-10; PMID:17936649; http://dx.doi.org/10.1016/j.cellbi.2007.08.013
103. Salmina K, Jankevics E, Huna A, Perminov D, Radovica I, Klymenko T, Ivanov A, Jascenko E, Scherthan H, Cragg M, et al. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Exp Cell Res 2010; 316:2099-112; PMID:20457152; http://dx.doi.org/10.1016/j.yexcr.2010.04.030
104. Erenpreisa J, Salmina K, Huna A, Kosmacek EA, Cragg MS, Ianzini F, Anisimov AP. Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation. Cell Biol Int 2011; 35:687-95; PMID:21250945; http://dx.doi.org/10.1042/CBI20100762
105. Erenpreisa J, Cragg MS. Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int 2013; 13:92; PMID:24025698; http://dx.doi.org/10.1186/1475-2867-13-92